Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.51 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | TDO2 | P48775 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492761 | 1.00 | TACR1 (0.51) | TACR1IDO1TDO2PDE2ACACNA1F | |
| SCHEMBL6917133 | 1.00 | TACR1 (0.51) | TACR1IDO1TDO2PDE2ACACNA1F | |
| SCHEMBL1728680 | 1.00 | TACR1 (0.51) | TACR1IDO1TDO2PDE2ACACNA1F | |
| SCHEMBL7939177 | 1.00 | TACR1 (0.51) | TACR1IDO1TDO2PDE2ACACNA1F | |
| Hydrochloric Acid SCHEMBL4471353 | 0.98 | TACR1 (0.50) | TACR1IDO1TDO2PDE2ACACNA1F | |
| Methane SCHEMBL4258949 | 0.98 | TACR1 (0.50) | TACR1IDO1TDO2PDE2ACACNA1F | |
| Hydrochloric Acid SCHEMBL7170075 | 0.98 | TACR1 (0.50) | TACR1IDO1TDO2PDE2ACACNA1F | |
| Hydrochloric Acid SCHEMBL17439064 | 0.98 | TACR1 (0.50) | TACR1IDO1TDO2PDE2ACACNA1F | |
| SCHEMBL29799650 | 0.88 | TACR1 (0.44) | TACR1IDO1TDO2PDE2ACACNA1F | |
| SCHEMBL29799603 | 0.88 | TACR1 (0.44) | TACR1IDO1TDO2PDE2ACACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118373777-A | Pyrimidine diketone derivative and preparation method and application thereof | 河北科技大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-114457125-B | Method for synthesizing (R) -1- [3,5-bis (trifluoromethyl) phenyl ] ethylamine by coupling transaminase and alcohol dehydrogenase | 浙江工业大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-115215941-A | Nano double-enzyme cascade reactor based on spontaneous isopeptide bond covalent self-assembly | 浙江工业大学 | 2022-10-21 | — | — | CN | disclosed |
| CN-114457125-A | Method for synthesizing (R) -1- [3,5-bis (trifluoromethyl) phenyl ] ethylamine by coupling transaminase and alcohol dehydrogenase | 浙江工业大学 | 2022-05-10 | — | — | CN | disclosed |
| EP-2578574-B1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | KOWA CO (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150320748-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150306098-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-10-29 | — | — | US | disclosed |
| US-8906895-B2 | Optically active dibenzylamine derivative, and method for preparing thereof | KOWA COMPANY, LTD. (JP) | 2014-12-09 | — | — | US | disclosed |
| EP-2789347-A1 | AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY | Kowa Company, Ltd. (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-6255349-B1 | PREVENTION REPRODUCTION; VIRICIDES | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034260-A2 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034268-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034258-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320748-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | SREBF1, SCD, SREBF2 | TACR1 1795/4885IDO1 2359/4885TDO2 4681/4885 |
| US-20150306098-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | SREBF1, SCD, SREBF2 | TACR1 1795/4885IDO1 2359/4885TDO2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.